Pfizer Inc. Stock
Price
Target price
€47.08
€47.08
0.560%
0.26
0.560%
?
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pfizer Inc. Stock
Pfizer Inc. gained 0.560% compared to yesterday.
Our community is currently high on Pfizer Inc. with 9 Buy predictions and 4 Sell predictions.
As a result the target price of €55.00 shows a slightly positive potential of 16.822% compared to the current price of €47.08 for Pfizer Inc..
For the coming years our community has positive and negative things to say abot the Pfizer Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Conscious of the environment" there were negative voices in the community.
Pros and Cons of Pfizer Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 0.560% | -3.821% | -11.073% | 18.712% | -8.106% | 51.375% | 75.854% |
| Eli Lilly Corp. | 0.020% | -2.194% | -11.396% | 29.813% | 18.390% | 187.409% | 324.099% |
| Merck & Co. Inc. | 0.580% | 1.651% | -8.200% | 34.603% | 26.653% | 12.680% | 62.213% |
| AbbVie Inc. | 1.470% | 1.504% | -9.778% | 42.137% | 15.642% | 133.322% | 130.355% |
Comments
News
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR)
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
Pfizer Inc. (NYSE: PFE) reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance